Park [Last Name Unknown]'s questions to Compass Pathways PLC (CMPS) leadership • Q1 2025
Question
An analyst from Morgan Stanley, on for Vikram Purohit, asked about the patient profile in the COMP005 trial compared to Phase IIb and the company's current stance on pursuing a large pharma partnership.
Answer
Dr. Guy Goodwin (CMO) confirmed the recruitment criteria for COMP005 are the same as Phase IIb, expecting a similar patient profile. CEO Kabir Nath added that the cap for prior psychedelic use was raised to 15%. Regarding partnerships, Mr. Nath reiterated the company's commitment to commercializing COMP360 independently in the U.S. and is not actively seeking a large pharma partner for that purpose.